163 related articles for article (PubMed ID: 36682790)
1. Usefulness of Serum Soluble Interleukin-2 Receptor Levels for Differentiating between PCNSL and SCNSL.
Mitobe Y; Matsuda KI; Sonoda Y
Neurol Med Chir (Tokyo); 2023 Mar; 63(3):111-115. PubMed ID: 36682790
[TBL] [Abstract][Full Text] [Related]
2. Measurement and cellular sources of the soluble interleukin-2 receptor in primary central nervous system lymphoma.
Kitai R; Sasaki H; Matsuda K; Tsunetoshi K; Yamauchi T; Neishi H; Matsumura K; Tsunoda A; Takeuchi H; Sato K; Kikuta K
Brain Tumor Pathol; 2013 Jan; 30(1):34-9. PubMed ID: 22399193
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
[TBL] [Abstract][Full Text] [Related]
4. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient.
Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023
[TBL] [Abstract][Full Text] [Related]
5. Results of combined-modality therapy for primary and secondary malignant lymphoma of the central nervous system (CNS).
Kawamura T; Koga S; Okamoto M; Kanno T; Iwamura H
Radiat Med; 2001; 19(3):145-9. PubMed ID: 11467381
[TBL] [Abstract][Full Text] [Related]
6. What is the Best Preoperative Quantitative Indicator to Differentiate Primary Central Nervous System Lymphoma from Glioblastoma?
Inoue A; Matsumoto S; Ohnishi T; Miyazaki Y; Kinnami S; Kanno K; Honda T; Kurata M; Taniwaki M; Kusakabe K; Suehiro S; Yamashita D; Shigekawa S; Watanabe H; Kitazawa R; Kunieda T
World Neurosurg; 2023 Apr; 172():e517-e523. PubMed ID: 36690204
[TBL] [Abstract][Full Text] [Related]
7. CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma.
Ikeguchi R; Shimizu Y; Shimizu S; Kitagawa K
Mult Scler; 2018 Aug; 24(9):1212-1223. PubMed ID: 28657431
[TBL] [Abstract][Full Text] [Related]
8.
Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
[TBL] [Abstract][Full Text] [Related]
9. Intraoperative Flow Cytometry Enables the Differentiation of Primary Central Nervous System Lymphoma from Glioblastoma.
Koriyama S; Nitta M; Shioyama T; Komori T; Maruyama T; Kawamata T; Muragaki Y
World Neurosurg; 2018 Apr; 112():e261-e268. PubMed ID: 29330078
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum and vitreous soluble interleukin-2 receptor in patients with intraocular lymphoma.
Suzuki K; Namba K; Kase S; Ogino Y; Hase K; Iwata D; Mizuuchi K; Hiraoka M; Kitaichi N; Ishida S
BMC Ophthalmol; 2022 Nov; 22(1):428. PubMed ID: 36357882
[TBL] [Abstract][Full Text] [Related]
11. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR; Dorris CS; Makambi KH; Luo Y; Munshi PN; Donato M; Rowley S; Saad A; Goy A; Dunleavy K; Ali A
Blood Adv; 2023 Jan; 7(1):32-39. PubMed ID: 36260735
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma.
Ohno M; Matsuzaki J; Kawauchi J; Aoki Y; Miura J; Takizawa S; Kato K; Sakamoto H; Matsushita Y; Takahashi M; Miyakita Y; Ichimura K; Narita Y; Ochiya T
JAMA Netw Open; 2019 Dec; 2(12):e1916953. PubMed ID: 31808923
[TBL] [Abstract][Full Text] [Related]
14. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
15. Performance of serum soluble interleukin-2 receptor as a diagnostic marker for lymphoma in patients with fever.
Kanda N; Yamaguchi R; Yamamoto Y; Matsumura M; Hatakeyama S
Sci Rep; 2023 Nov; 13(1):18784. PubMed ID: 37914769
[TBL] [Abstract][Full Text] [Related]
16. Machine learning applications for the differentiation of primary central nervous system lymphoma from glioblastoma on imaging: a systematic review and meta-analysis.
Nguyen AV; Blears EE; Ross E; Lall RR; Ortega-Barnett J
Neurosurg Focus; 2018 Nov; 45(5):E5. PubMed ID: 30453459
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Value of sLR11 and sIL-2R in the Cerebrospinal Fluid for Malignant Central Nervous System Lymphoma.
Shimizu N; Nakao S; Hasunuma H; Nakaseko C; Shimizu T; Ebinuma H; Bujo H
Intern Med; 2024 Mar; ():. PubMed ID: 38432983
[TBL] [Abstract][Full Text] [Related]
18. Parenchymal central nervous system involvement in aggressive B-cell lymphoma: retrospective analysis of clinical and MRI features in a Chinese population.
Wu Y; Wang Y; Sun X; Bai X; Qian J; Zhu H; Cui Q; Xing R; Chen Y; Liu Q; Guo J; Ji N; Sun S; Liu Y
BMC Neurol; 2019 Nov; 19(1):268. PubMed ID: 31684888
[TBL] [Abstract][Full Text] [Related]
19. Differentiation between primary CNS lymphoma and glioblastoma: qualitative and quantitative analysis using arterial spin labeling MR imaging.
You SH; Yun TJ; Choi HJ; Yoo RE; Kang KM; Choi SH; Kim JH; Sohn CH
Eur Radiol; 2018 Sep; 28(9):3801-3810. PubMed ID: 29619520
[TBL] [Abstract][Full Text] [Related]
20. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
